Intelligent Bio Solutions Profit Margin

Intelligent Bio Solutions (GBS) currently reports a profit margin of -294.91% as of June 2026. That compares with -346.23% in the prior-year period — up 14.8% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore Intelligent Bio Solutions's profit margin history and peer comparisons.

Intelligent Bio Solutions's profit margin increased from -346.23% to -294.91% — a 14.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intelligent Bio Solutions's profit margin of -294.91% is lower than the Healthcare sector average of 19.13%. That is roughly 1641.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Intelligent Bio Solutions's current -294.91% should be judged against Healthcare norms (sector average: 19.13%) and against GBS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -294.91%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Intelligent Bio Solutions, and consider following GBS for alerts when major investors trade the stock.